
The dual-incretin medication
Compounded tirzepatide
A synthetic peptide that activates both GIP and GLP-1 receptors, prepared by a state-licensed 503A pharmacy on a per-prescription basis. Shipped discreetly after clinician authorization.
Medical wellness programs
You’ll talk to Kris or Dr. Lula
A weekly injection that works on both the GIP and GLP-1 pathways. Kris or Dr. Lula review your history and labs, decide with you whether it fits, and adjust the dose with you month by month. Compounded by a state-licensed 503A pharmacy. Telehealth in Michigan, Florida, Alabama, Mississippi, Georgia, Colorado, Pennsylvania, Ohio, Arkansas and Arizona. From $265/mo. Free consultation.

Your clinicians
Kris Cutaj, MSPAS, PA-C, FAACM
Board-certified physician assistant
Kris and Dr. Lula decide with you whether tirzepatide fits, then adjust the dose month by month.
Working with Dr. Lula
Compounded Tirzepatide
from $265/mo
Medication, monthly check-ins, labs and dose titration.
Medically reviewed by
Dr. Erald Lula, MD, MPH
Triple Board-Certified: Internal Medicine, Obesity Medicine, Lifestyle Medicine
Last reviewed: Bio
Every tirzepatide plan combines the compounded dual-incretin medication, care from Kris or Dr. Lula, and the labs and dose changes that keep a GIP + GLP-1 protocol on track over time.

The dual-incretin medication
A synthetic peptide that activates both GIP and GLP-1 receptors, prepared by a state-licensed 503A pharmacy on a per-prescription basis. Shipped discreetly after clinician authorization.
Your clinicians
Licensed in your state. Free 20-minute consultation reviewing your full medical history. Monthly check-ins and direct messaging.
Your labs and dose
Baseline labs before any prescription. Gradual titration over the first 16 to 20 weeks across both pathways. Quarterly labs and response tracking with your clinician.
“Pricing posted up front: Compounded Tirzepatide from $265 / month. Your clinician determines whether a personalized compounded program is clinically appropriate for you at the consultation.”
Tirzepatide is a synthetic peptide that activates two incretin receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Semaglutide is a single-pathway GLP-1 agonist; tirzepatide is dual.
A “compounded” medication is one prepared by a state-licensed compounding pharmacy on a prescription-by-prescription basis. NuHealth’s compounded tirzepatide is prepared by a 503A compounding pharmacy when your NuHealth clinician determines that a personalized formulation fits your clinical situation. This per-patient framework is what allows ongoing compounding of tirzepatide under current FDA rules.
Compounded tirzepatide is not FDA-approved as a finished drug product, and is not Mounjaro® or Zepbound® (the FDA-approved finished drugs by Eli Lilly). Your NuHealth clinician will explain how this affects your treatment plan during your consultation.

How it works in the body
GIP pathway
Activates the GIP receptor — glucose-dependent insulinotropic polypeptide.
GLP-1 pathway
Activates the GLP-1 receptor — the same target a single-incretin GLP-1 hits alone.
Energy + appetite regulation
Together the two pathways influence satiety, glucose handling, and energy.

Kris or Dr. Lula reviews your medical history, weight history, prior GLP-1 response (if any), and any medications or conditions that may affect candidacy for a dual-incretin program. If you are not a candidate for compounded tirzepatide, they talk through alternatives. The consultation itself is free.

Kris or Dr. Lula orders baseline labs (typically HbA1c, lipid panel, kidney function, and a metabolic panel), reviews your results, and confirms whether a personalized compounded tirzepatide program is appropriate for you. If they authorize treatment, your prescription is sent to our 503A compounding pharmacy partner.

Monthly check-ins with Kris or Dr. Lula. Quarterly labs to track how your body responds across both pathways. Your clinician adjusts dose, slows titration, or recommends a different protocol entirely if side effects are limiting. You can message your clinician directly between appointments.
Throughout, your treatment plan is the responsibility of your NuHealth clinician, informed by your full medical history, labs, and response across both incretin pathways.
Candidacy
Compounded tirzepatide may be appropriate for adults whose clinician determines that a dual-incretin medication fits their clinical situation. Here is how candidacy is generally framed before your consultation.
Clinician-assessed at your consultation
Many patients describe a quieting of food noise plus steadier mid-day energy. The GLP-1 pathway is the one a single-incretin agonist hits; the GIP pathway also influences insulin secretion, so glucose handling often feels more stable between meals. Individual response varies; your clinician tracks your specific timeline at every check-in.
Weeks 1-2
Starting dose · 2.5 mg weekly
Your clinician starts you low, at 2.5 mg weekly, so your body adjusts to dual-receptor onboarding. Many patients describe early appetite changes; mild nausea is the most common side effect and usually resolves.
Week 4
First titration · often 5 mg
A check-in decides the first step up. If the starting dose is well-tolerated, your clinician may increase it (commonly to 5 mg).
Week 12
7.5-10 mg range · full rhythm
By three months, many patients have settled into a stable dose with their clinician. At each check-in your clinician reviews progress, side effects, and labs.
Week 24
Outcomes review · 12.5-15 mg band
Around six months your clinician does a full review. Some patients move to a lower-dose maintenance phase; others continue at a 12.5 or 15 mg maintenance band.
The pattern above is what patients commonly describe. It is not a guarantee of outcome. Your clinician tailors the plan to your specific metabolic profile, labs, and goals.
The program at a glance
Tirzepatide acts on two incretin pathways. Your clinician starts you at a low dose and titrates gradually, reviewing how you respond at every check-in. Compounded tirzepatide is prepared per-patient by a state-licensed 503A pharmacy. Individual results vary — your plan is built around your biology, under medical supervision.
Pharmacy
503A
State-licensed compounding
Reply time
<24h
Typical reply on the patient portal
States
10
MI · FL · AL · MS · GA · CO · PA · OH · AR · AZ
Google rating
5.0★
From verified patients

The medication
Compounded tirzepatide
Prepared to your clinician’s prescription by a state-licensed 503A compounding pharmacy.
Free 20-minute consultation · Your clinician decides candidacy
Pricing
The compounded tirzepatide program covers the medication, clinician check-ins, labs, and dose titration across both GIP and GLP-1 pathways. Transparent pricing, no insurance middleman.
Free consultation
Free. No charge for the visit, whatever the outcome.
No hidden fees
The monthly price covers medication, clinician care, and labs.
Cancel anytime
Programs continue only when you and your clinician agree.
GIP + GLP-1 dual receptor agonist, prepared per prescription.
3-month starter program
A free 20-minute consultation with your clinician comes before any prescription.
CareCredit · Financing partner
GLP-1 programs run $125–$265 a month. With CareCredit, split the medication, labs, and follow-through over a longer schedule. Prequalification has no impact on your credit score.
Check your prequalificationCareCredit is a financing product from Synchrony Bank. NuHealth Medical Wellness does not own, operate, or set the terms of CareCredit. Approval, rates, and terms are determined by Synchrony at application.

In-person consults for patients in metro Detroit. Telehealth in Michigan, Florida, Alabama, Mississippi, Georgia, Colorado, Pennsylvania, Ohio, Arkansas, and Arizona. The medication ships to your door; when you need to walk in for labs, an in-person visit, or a dose discussion, our clinic is on Woodward, between Birmingham and Berkley.
NuHealth Medical Wellness30301 Woodward Ave, Suite 240Three topics, in plain language. If you do not see your question, the free consultation is the place to ask it.
Tirzepatide is a synthetic peptide that activates two incretin receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). A compounded preparation is one prepared by a state-licensed compounding pharmacy on a per-prescription basis. NuHealth’s compounded tirzepatide is prepared by our 503A pharmacy partner when your clinician determines a personalized formulation is appropriate for your situation. It is not FDA-approved as a finished drug product.
Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both the GIP and the GLP-1 receptors. Some patients respond better to one approach versus the other; the right choice depends on your medical history, prior treatment response, and lab profile. Your NuHealth clinician helps determine which medication fits your specific situation.
Many patients describe noticing appetite changes within the first 1–2 weeks. Measurable changes typically appear later. Your clinician tracks your specific timeline at every check-in. Individual response varies.
$265/month. The monthly price includes the medication (when prescribed), clinician check-ins, lab orders and your clinician’s review of the results, dose titration, and direct messaging with your clinician. Lab fees are billed separately by the lab. The 20-minute consultation with your clinician is free. NuHealth does not bill insurance.
No. NuHealth’s compounded tirzepatide is not Mounjaro® or Zepbound®. Those are FDA-approved finished drug products manufactured and tested by Eli Lilly (Mounjaro for type 2 diabetes, Zepbound for chronic weight management). NuHealth’s compounded tirzepatide is prepared by a state-licensed 503A compounding pharmacy on a per-prescription basis and is not FDA-approved as a finished drug product. Clinical-trial outcomes from FDA-approved branded products do not transfer to compounded preparations. Your clinician will explain the distinction during your consultation.
If you remember within 4 days of your scheduled dose, take it as soon as you remember and continue your normal weekly schedule. If more than 4 days have passed, skip the missed dose and continue with your next scheduled one. Don’t double up. If you have questions about dosing, message your clinician.
Yes — tirzepatide is a subcutaneous injection, given once a week. The needles are very fine (similar to insulin pens). Your clinician walks you through the technique at your first appointment.
Many patients regain some weight when they stop. Your clinician will work with you on a tapering plan if you decide to discontinue. Some patients move to a lower-dose maintenance schedule with their clinician; others step down over months as lifestyle changes take hold. The plan is individualized.

From a patient
“After a year of partial progress on a single-pathway GLP-1, switching changed the whole conversation about my biology.”
Tom L.
Tirzepatide Program
Step one
Labs reviewed first
Then
Titrate monthly check-ins
Individual results vary
The next step
NuHealth provides telehealth care to adults in Michigan, Florida, Alabama, Mississippi, Georgia, Colorado, Pennsylvania, Ohio, Arkansas, and Arizona, with in-person consultations available at our Royal Oak, MI clinic. Start with a free 20-minute consultation. Your clinician decides whether it’s appropriate, based on your medical history and labs.